Aventa Lymphoma

Replace multiple FISH panels for fusion and rearrangement detection with a single, comprehensive test

Whole-genome | Reports on 417 genes

The Aventa Lymphoma test gives you an integrated approach for evaluating all clinically relevant rearrangements in B- and T-cell lymphomas so that you can:

Accurately diagnose disease and classify subtypes | Refine patient risk assessment to inform treatment decisions | Choose the most effective therapy to optimize outcomes

~35%

FISH testing misses ~35% of diagnosis-, prognosis- and treatment-informing fusions and rearrangements

Find them with Aventa Lymphoma

Case Study

Presentation: Aggressive non-Hodgkin B-cell lymphoma

  • Morphological features are most compatible with Burkitt lymphoma

  • FISH testing for MYC-r was negative

  • Aventa Lymphoma testing detected cryptic IgH::MYC rearrangement missed due to design of break-apart FISH probes

  • Oncologist added CNS prophylaxis to treatment plan

Aventa Lymphoma resolved diagnosis and identified need for more aggressive treatment

Presentation: Atypical lymphoid infiltrate

  • Pathology consistent with primary cutaneous T-cell lymphoma, NOS with T-follicular helper phenotype

  • Aventa Lymphoma testing detected unanticipated TRA::TCL1A rearrangement, along with an otherwise complex karyotype

  • Rearrangement prompted reconsideration of diagnosis to T-cell prolymphocytic leukemia (T-PLL)

  • Confirmatory TCL1A IHC and FISH studies are underway

Aventa Lymphoma changed diagnosis

Presentation: Snoring evaluation finds abnormal follicular growth

  • Cells expressed IRF4

  • IRF4 rearrangement negative via commercial FISH and DNA/RNA NGS testing

  • Aventa Lymphoma testing detected IgH::IRF4 rearrangement that was missed because one of the break-apart FISH probes used previously targeted a region deleted in this patient

  • With IRF4-driven lymphoma confirmed, patient received mild chemotherapy – an alternative diagnosis such as DLBCL or follicular lymphoma could have resulted in more aggressive treatment

  • Patient achieved complete remission

Aventa Lymphoma resolved diagnostic dilemma and informed optimal treatment

Presentation: Diffuse B-Cell Lymphoma

  • FISH testing for MYC was positive, FISH testing for BCL2 was negative – patient diagnosed as single-hit DLBCL and treated using standard chemotherapy

  • Retrospective Aventa Lymphoma testing detected IgL::BCL2 rearrangement that had been missed because dual fusion FISH probes targeting the wrong partner (IgH::BCL2 ) were used

  • Patient passed away within 9 months of diagnosis; presence of BCL2 rearrangement would have classified patient as higher-risk double-hit DLBCL and possibly changed treatment selection

Aventa Lymphoma would have prompted consideration of more aggressive treatment

Presentation: Lymphoma diagnosed as DLBCL

  • FISH testing for MYC and BCL2 was negative; FISH testing for BCL6 was positive – a diagnosis of single-hit DLBCL was made, and standard R-CHOP treatment was administered

  • Retrospective Aventa Lymphoma testing detected IgH::CCND1 rearrangement, which was confirmed by IHC -- CCND1 was not tested for via FISH due to DLBCL diagnosis

  • Patient progressed and passed away within 8 months of diagnosis

  • Detection of CCND1 rearrangement would have prompted reconsideration of diagnosis to aggressive mantle cell lymphoma and alternative treatment, with potentially improved outcome

Aventa Lymphoma would have changed diagnosis and treatment selection

FISH vs Aventa Lymphoma

Conventional FISH:
narrow in scope

Although commonly used to detect fusions and rearrangements in lymphoma, FISH has key limitations:

  • Assay is not highly multiplexable, must probe each target individually, often done sequentially, consuming additional time and tissue

  • Requires anticipation of relevant targets — incorrect initial diagnosis can lead to appropriate targets remaining untested

  • May fail to detect clinically significant variants involving atypical breakpoints or noncanonical partner genes or other rare biomarkers

Aventa Lymphoma: single-assay, genome-wide coverage

The Aventa Lymphoma test overcomes these constraints through a comprehensive, one-step approach:

  • All-in-one testing — Assesses 417 genes at once, reducing time and tissue requirements

  • Diagnosis-agnostic detection of all rearrangements, ensuring even the rarest are found

  • Technology is robust to cryptic breakpoints and detects rearrangements regardless of partner

  • Enhanced sensitivity — Delivers a 100- to 1000-fold higher signal than FISH

Ordering Aventa tests is easy

We handle specimen retrieval and return, and results are returned in about 10 business days.

We are committed to making our tests accessible and affordable

Aventa Assist offers programs to help patients whose costs for Aventa tests are not fully covered by insurance.